EGFR and non-small cell lung carcinoma: Clinical trials with other third generation TKIs targeting EGFR mutations in a neoadjuvant setting (such as the NEOADAURA study (comparison of treatment with osimertinib versus osimertinib and chemotherapy versus placebo and chemotherapy) or the afatinib trial (NCT04470076 trial)) have also been developed for early operable stages of NSCLC [23].